Patents by Inventor Andres Fernandez
Andres Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090270273Abstract: Devices formed as optically readable substrates are provided having a high feature density (e.g., attachment or deposition sites) in arrays comprising macromolecules, specifically amplicons, and devices and methods are provided for analysis of target nucleic acids having an undetermined sequence.Type: ApplicationFiled: April 21, 2009Publication date: October 29, 2009Applicant: Complete Genomics, Inc.Inventors: Norman Burns, Andres Fernandez, Karen Shannon
-
Publication number: 20090117006Abstract: Substrates are provided for use in the detection, identification and analysis of biologic or chemical samples that are labeled with a fluorescent label, in which the plane of maximum fluorescence is displaced from a reflective substrate surface so that the intensity maximum of the standing wave interference pattern of incident and reflected probe radiation is enhanced. The format of the substrates includes substantially planar surfaces as well as substrates with introduced variations to the substrate surface, e.g., depressions, wells, pedestals and the like, disposed in arrays or other similar structures such that one or more fluorophore-comprising objects can be attached thereto.Type: ApplicationFiled: October 30, 2008Publication date: May 7, 2009Applicant: Complete Genomics, Inc.Inventor: Andres Fernandez
-
Publication number: 20090088438Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)-B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed herein. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: June 25, 2008Publication date: April 2, 2009Applicant: LABORATORIOS SALVAT, S.A.Inventors: Carmen SERRA COMAS, Anna FERNANDEZ SERRAT, Dolors BALSA LOPEZ, Isabel MASIP MASIP, Juan Lorenzo CATENA RUIZ, Jose HIDALGO RODRIGUEZ, Carmen LAGUNAS ARNAL, Carolina SALCEDO ROCA, Andres FERNANDEZ GARCIA
-
Patent number: 7508572Abstract: A MEMS-based mirror is provided with trenches between adjacent electrodes in order to be able to withstand relatively high applied voltages, and thus has a substantially reduced exposure to uncontrolled surface potentials. The MEMS-based mirror, thus avoids voltage drifts and has an improved mirror position stability. The trench dimensions are selected such that the voltage applied between each adjacent pair of electrodes stays within predefined limits. An insulating layer, such as silicon dioxide, electrically isolates each pair of adjacent electrodes. Each insulting layer extends partially above an associated trench and is characterized by the same height and width dimensions.Type: GrantFiled: November 14, 2006Date of Patent: March 24, 2009Assignee: Glimmerglass Networks, Inc.Inventors: Bryan P. Staker, Andres Fernandez, Windsor Owens, Alexander P. Kindwall
-
Patent number: 7452904Abstract: Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X? is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.Type: GrantFiled: December 18, 2002Date of Patent: November 18, 2008Assignee: Chiesi Farmaceutici S.p.A.Inventors: Juan Lorenzo Catena Ruiz, Carles Farrerons Gallemi, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Natividad Toledo Mesa, Andrés Fernandez Garcia
-
Patent number: 7423172Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)s—N(R4)—B-J-T; and s. R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: GrantFiled: July 29, 2005Date of Patent: September 9, 2008Assignee: Laboratorios Salvat, S.A.Inventors: Carmen Serra Comas, Anna Fernández Serrat, Dolors Balsa López, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernández García
-
Publication number: 20080189011Abstract: An electric power assisted steering apparatus for a vehicle, comprises a steering mechanism, which operatively connects a steering wheel to the road wheels of the vehicle, an electric motor operatively connected to the steering mechanism, a torque sensing means adapted to produce a first output signal indicative of the torque carried by a portion of the steering mechanism, a vehicle speed sensing means for producing a second output signal indicative of the speed of the vehicle, a signal processing unit adapted to receive the first and second signals and to produce a torque demand signal representative of a torque to be applied to the steering mechanism by the motor; and a motor drive stage adapted to provide a drive current to the motor responsive to the torque demand signal.Type: ApplicationFiled: March 18, 2005Publication date: August 7, 2008Inventors: Angel Luis Andres Fernandez, Andrew James Stephen Williams, George Thomas Dibben
-
Publication number: 20080137172Abstract: An array of MEMS devices is formed on a planar substrate having in each of a plurality of annular regions or sectors a plurality of MEMS mirrors of substantially identical structure, wherein the MEMS mirrors in each region have an identical pre-tilt. The pre-tilt is achieved by embedding each dual-axis tiltable mirror within a pre-tilted microplatform or gimbal. In a specific embodiment, one microplatform of a preselected pre-tilt is provided for each micromirror and an underlying electrode is provided having a shape conforming with the pre-tilt. In a specific embodiment, the annular regions are contiguous elliptical or ovoidal regions. By pre-tilt, it is meant that the rest state or nonactuated state of the micro-mirror is such that a reflected beam from a fixed source is directed to the center of a target array.Type: ApplicationFiled: December 6, 2006Publication date: June 12, 2008Applicant: Glimmerglass Networks, Inc.Inventors: Bryan P. Staker, Andres Fernandez, Windsor E. Owens, Alexander P. Kindwall
-
Publication number: 20080125378Abstract: The compounds of formula (1), wherein n is an integer from 0 to 4; R1 is a radical selected from the group consisting of H, CH3, CH2-CH3, C(CH3)3, COOH, CONH2 and C=CH; R2, R3, R4 and R5 are radicals independently selected from the group consisting of H, F, Cl, Br, (C1-C3)-alkoxyl and (C1-C4)-alkyl; and R6 is a radical selected from the group consisting of H, F, Cl, Br, (C1-C3)-alkoxyl, (C1-C4)-alkyl, R7, CH=CH-R7 and O-CH2-R7; wherein R7 is phenyl or phenyl mono- or independently di-substituted with F, Cl, Br, (C1-C3)-alkoxyl or (C1-C4)-alkyl, exhibit a similar chemotactic index to that of amygdalin (natural product whose chemotaxis profile is similar to that of peptide T) and, consequently, are useful for treating inflammatory and/or allergic dermatophathies, such as psoriasis, and are especially much less toxic than amygdalin.Type: ApplicationFiled: May 29, 2007Publication date: May 29, 2008Applicant: UNIVERSITAT POLITECNICA DE CATALUNYAInventors: Juan Jesus Perez Gonzalez, Amadeu Llebaria Soldevilla, Carmen Lagunas Arnal, Andres Fernandez Garcia
-
Publication number: 20080113160Abstract: One or more cavities are formed in the bonding surfaces of one, all, or some of the elements to be bonded. These cavities serve as receptacles for the bonding material and are where the bonds are localized. The cavities are of sufficient size and shape so that their volume is greater than the volume of bonding material forming the bond. This ensures that when the elements are brought into contact with one another to mate, the bonding material, which can flow prior to solidifying into a bond, will flow into the cavities and will not impede the separation of the parts. This allows the parts to be mated with nominally zero separation. Once solidified, the bonding material forms a localized bond inside each cavity. Different cavity shapes, such as, rectangular, circular, or any other shape that can be injected or filled with adhesive material may be used.Type: ApplicationFiled: November 14, 2006Publication date: May 15, 2008Applicant: Glimmerglass Networks, Inc.Inventors: Andres Fernandez, Bryan P. Staker, Alexander P. Kindwall, Windsor E. Owens
-
Publication number: 20080112038Abstract: A MEMS-based mirror is provided with trenches between adjacent electrodes in order to be able to withstand relatively high applied voltages, and thus has a substantially reduced exposure to uncontrolled surface potentials. The MEMS-based mirror, thus avoids voltage drifts and has an improved mirror position stability. The trench dimensions are selected such that the voltage applied between each adjacent pair of electrodes stays within predefined limits. An insulating layer, such as silicon dioxide, electrically isolates each pair of adjacent electrodes. Each insulting layer extends partially above an associated trench and is characterized by the same height and width dimensions.Type: ApplicationFiled: November 14, 2006Publication date: May 15, 2008Applicant: Glimmerglass Networks, Inc.Inventors: Bryan P. Staker, Andres Fernandez, Windsor Owens, Alexander P. Kindwall
-
Publication number: 20070276043Abstract: Compounds of general formula I, and the salts and solvates thereof, wherein R1 represents the radical 2-benzoylphenylamino; R2 represents —(CH2)s—N(COR3)-A-J-T or —(CH2)S—N(R4)—B-J-T; and s, R3, R4, A, B, J and T have the meanings disclosed in the description. These compounds are PPAR? modulators and, therefore, are useful for the treatment or prevention of a condition or a disease mediated by these receptors.Type: ApplicationFiled: July 29, 2005Publication date: November 29, 2007Inventors: Carmen Serra Comas, Anna Fernandez Serrat, Dolors Balsa Lopez, Isabel Masip Masip, Juan Lorenzo Catena Ruiz, Jose Hidalgo Rodriguez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
-
Patent number: 7115629Abstract: The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1–C4)-alkylthio, (C1–C4)-alkoxyl, (C1–C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1–C4)alkyl and (C1–C4)alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.Type: GrantFiled: June 23, 2004Date of Patent: October 3, 2006Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Juan Lorenzo Catena Ruiz, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, José Ignacio Bonilla Navarro, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernandez Garcia
-
Patent number: 7100735Abstract: An electric power assisted steering system comprising a steering mechanism which operatively connects a steering wheel to the road wheels of the vehicle, a torque sensing means (6) adapted to produce a first output signal indicative of the torque carried by a portion of the steering mechanism (7), a means (6) for producing a second output signal indicative of the angular velocity of the steering wheel, a difference means (21) for determining the difference in value of the torque carried by a portion of the column between two points in time to produce a third output value, an electric motor (1) operatively connected to the steering mechanism, a signal processing unit (7) adapted to receive the two signals and to produce a torque demand signal representative of a torque to be applied to the steering mechanism by the motor (1), and a motor drive stage adapted to provide a drive current to the motor (1) responsive to the torque demand signal, and in which the torque demand signal (1) includes a damping componentType: GrantFiled: October 7, 2004Date of Patent: September 5, 2006Assignee: TRW LucasVarity Electric Steering LimitedInventors: Tony Burton, Angel L. Andres Fernandez
-
Publication number: 20060189631Abstract: Compounds of general formula (I), wherein from A1 to A5, and from B1 to B5 are H, alkyl, alkoxyl, halogen, carboxylic derivatives or sulfur derivatives, among others; and from P1 to P3 are H, halogen, alkyl or alkoxyl, among others. Said compounds may be used for the chemoprevention and treatment of both precancerous lesions and cancer.Type: ApplicationFiled: January 27, 2006Publication date: August 24, 2006Applicant: LABORATORIOS S.A.L.V.A.T., S.A.Inventors: Juan Catena Ruiz, Carles Gallemi, Anna Serrat, Carmen Comas, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andres Fernandez Garcia
-
Publication number: 20060160894Abstract: Compounds of general structure (I), wherein the central benzene ring may be substituted in the meta- or para-position; -A is an optionally substituted hydroxyl, alkoxyl, hydroxylamine, alkoxylamine or amine radical; -W is an N- and C-linked biradical selected from several possibilities; and -Z is a carbon radical selected from several possibilities. These compounds are PPAR? and PPAR?/PPAR? modulators and, therefore, are useful for the prophylactic and/or curative treatment of a condition or a disease mediated by these recetpcors.Type: ApplicationFiled: June 11, 2004Publication date: July 20, 2006Applicant: LABORATORIOS S.A.L.V.A.T.,S.A.Inventors: Anna Fernandez Serrat, Carmen Serra Comas, Dolors Balsa Lopez, Amadeu Llebaria Soldevila, Carles Farrerons Gallemi, Ignacio Miquel Bono, Juan Catena, Carmen Lagunas Arnal, Arnau Cordomi Montoya, Carolina Salcedo Roca, Natividad Toledo Mesa, Pedro Marrero Gonzalez, Diego Haro Bautista, Andres Fernandez Garcia
-
Publication number: 20050150711Abstract: An electric power assisted steering system comprising a steering mechanism which operatively connects a steering wheel to the road wheels of the vehicle, a torque sensing means (6) adapted to produce a first output signal indicative of the torque carried by a portion of the steering mechanism (7), a means (6) for producing a second output signal indicative of the angular velocity of the steering wheel, a difference means (21) for determining the difference in value of the torque carried by a portion of the column between two points in time to produce a third output value, an electric motor (1) operatively connected to the steering mechanism, a signal processing unit (7) adapted to receive the two signals and to produce a torque demand signal representative of a torque to be applied to the steering mechanism by the motor (1), and a motor drive stage adapted to provide a drive current to the motor (1) responsive to the torque demand signal, and in which the torque demand signal (1) includes a damping componentType: ApplicationFiled: October 7, 2004Publication date: July 14, 2005Inventors: Tony Burton, Angel Andres Fernandez
-
Patent number: 6916828Abstract: The invention relates to carbamates having general structure (I), wherein: R1, R2 and R3 are H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio, (C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1-C4)-alkyl and (C1-C4)-alkyl substituted by one or several F or OH radicals; R4 represents a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not). The amine of the quinuclidine ring can also be forming quatemary ammonium salts or in an oxidized state (N-oxide). Carbamates (I) are antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. Hence, they can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmologic operations.Type: GrantFiled: June 25, 2001Date of Patent: July 12, 2005Assignee: Laboratorios S.A.L.V.A.T., S.A.Inventors: Carles Farrerons Gallemi, Juan Lorenzo Catena Ruiz, Anna Fernandez Serrat, Ignacio José Miquel Bono, Dolors Balsa Lopez, José Ignacio Bonilla Navarro, Carmen Lagunas Arnal, Carolina Salcedo Roca, Andrés Fernandez Garcia
-
Publication number: 20050043349Abstract: Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO2, SH, CN, F, Cl, Br, I, COOH, CONH2, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X? is a physiologically acceptable anion. Carbamate (I) is selective M3 receptor antagonists versus M2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions.Type: ApplicationFiled: December 18, 2002Publication date: February 24, 2005Applicant: Laboratorios S.A.L.V.A.T.Inventors: Juan Catena Ruiz, Carles Farrerons Gallemi, Anna Fernandez Serrat, Ignacio Miquel Bono, Dolors Balsa Lopez, Carmen Lagunas Arnal, Carolina Salcedo Roca, Natividad Toledo Mesa, Andres Fernandez Garcia
-
Publication number: 20050014806Abstract: Compounds of formula (I), wherein X is O, S, NH, OCO, NH—CO, NH—COO, NH—CO—NH, NH—CS or NH—CS—NH; R4 is H, (C1-C3)-alkyl optionally substituted by halogen, or a C-linked heterocyclic radical selected from several possibilities; R1 and R3 are H or F; and R2 is an N-linked or C-linked heterocyclic radical, are useful in the treatment of microbial infections in human or animal body.Type: ApplicationFiled: July 17, 2002Publication date: January 20, 2005Inventors: Carles Farrerons Gallemi, Carmen Lagunas Arnal, Anna Fernandez Serrat, Juan Catena Ruiz, Ignacio Miquel Bono, Dolors Balsa Lopez, Carolina Salcedo Roca, Natividad Toledo Mesa, Andres Fernandez Garcia